Business Standard

Sun Pharma's specialty business gets USFDA boost

Stock gained over 6% as FDA accepts application for new ophthalmic drug

sun pharma
Premium

A logo of Sun Pharmaceutical Industries Ltd is pictured at its research and development centre in Mumbai (Photo: Reuters)

Aneesh Phadnis Mumbai
Sun Pharmaceutical Industries’s ophthalmic business in the US has received a boost, with the US Food and Drug Administration (USFDA) accepting the company’s application for a novel medicine to treat dry-eye disease.

Investors cheered the development and the company stock gained 6.89 per cent to close at Rs 577.70 on the BSE on Wednesday. 

Sun Pharma is building its specialty drugs business in the US through acquisitions, increased spending on research and development, and dedicated sales teams.

Currently, the company markets four specialty drugs in the US, and overall the market contributed about 30 per cent to the company’s revenue

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in